TNDM

Tandem is a credible #2/3 in insulin pump AID with a differentiated portfolio (t:slim X2 + Mobi) and clinically validated Control-IQ+ technology — the MD&A flags 500,000 users across 25+ countries, 2025 CE Mark for Mobi with Control-IQ+, December 2025 Mobi Android launch in the US, and the 2025 expansion into Type 2 intensive-insulin users. Revenue growth re-accelerated to +7.9% in FY2025 to $1.01B and gross margin held at 53.8% (gross profit +11.5% YoY), so the commercial engine is working and the four-year US pump reimbursement cycle plus the new pharmacy-benefit channel offer a visible volume tailwind.

The problem is what sits below the gross line. FY2025 operating income deteriorated to -$187M (operating margin -18.5%) and net loss widened to -$205M from -$96M, with diluted EPS of -$3.04. Operating cash flow flipped to -$9.7M (from positive a year earlier, YoY -140%) while the company still spent $19.9M on capex — so free cash flow is negative even before debt service. The balance sheet is the bigger concern: $310M long-term debt against just $90.6M cash, equity down 41% to $155M, accumulated deficit of -$1.25B, and liabilities/equity of 4.68x. Management explicitly states in Risk Factors that it has incurred losses since inception, has a $1.3B accumulated deficit, and 'cannot assure' sustained profitability — and that expenses will continue to rise as it invests in Mobi international launches, Sigi patch pump, and extended-wear infusion sets.